Part of Vanderbilt University
Clinical Trials
832
108 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1925
Active, not recruiting
64
7.7%
Approved For Marketing
1
0.1%
Completed
463
55.6%
Enrolling By Invitation
27
3.3%
Not yet recruiting
17
2.0%
Recruiting
117
14.1%
Suspended
1
0.1%
Terminated
71
8.5%
Unknown
8
1.0%
Withdrawn
63
7.6%
No approval data available
- Dolly Parton donated $1 million to Vanderbilt University Medical Center in 2020, creating the Dolly Parton COVID-19 Research Fund to support COVID-19 research. - Vanderbilt confirmed Parton's funding supported what a researcher described as "critical" early stages of research connected to Moderna's COVID-19 vaccine. - The early-stage trial of the Moderna vaccine that her donation helped fund found it offered nearly 95% protection against severe COVID-19. - Parton later donated another $1 million to Vanderbilt for pediatric infectious disease research, including infections in children with cancer.
- Dolly Parton made a $1 million donation to Vanderbilt University Medical Center in March 2020 to support research into COVID-19 treatments, creating the Dolly Parton COVID-19 Research Fund. - The fund supported early-stage research that contributed to the COVID-19 vaccine developed by Moderna and the National Institute of Allergy and Infectious Diseases. - More than 250 million people globally received the Moderna COVID-19 vaccine, and COVID vaccinations overall are estimated to have saved at least 14 million lives in the first year of rollout. - Parton, who died this week at age 80 after a brief battle with cancer, also gave another $1 million in 2022 for pediatric infectious disease research.
- The 53rd Annual Medical Student Research Day at the Whiddon College of Medicine will take place on Friday, July 24, 2026, showcasing summer research from 69 medical students. - The eight-week summer research program included 58 rising M2 students and 11 incoming M1 students conducting basic, clinical, and translational research alongside faculty mentors. - Julie A. Bastarache, M.D., from Vanderbilt University Medical Center will deliver the keynote lecture titled "A Series of (Un)fortunate Events: My Journey from Fellow to Tenure." - Winners of the Clyde G. "Sid" Huggins Medical Student Research Awards, honoring the college's first dean of students, will be announced following the poster sessions.
- CDC surveillance data from 2009–2023 documented 402 tetanus cases and 37 deaths, with nearly half of patients having never received a tetanus vaccine. - Four pediatric tetanus cases occurred in 2024 alone, matching the typical annual national total, all in children who had not completed the primary vaccination series. - U.S. tetanus cases rose from 18 in 2023 to 33 in 2025, prompting public health experts to warn about growing vaccine hesitancy. - Tetanus remains entirely preventable through vaccination; the bacteria persist in soil and the environment and cannot be eliminated.
- Tae Hyun Hwang, PhD, presented a novel four-agent AI system at AACR 2026 designed to provide oncologists with maximally contextualized, data-informed treatment guidance across all cancer indications. - The system chains four agentic AI platforms—Cartographer, Witness, Scout, and Terrain—to process histopathology images, model drug-tumor dynamics, predict metastatic trajectories, and convene a virtual tumor board. - Hwang emphasized the system's goal is to minimize missed opportunities in cancer care by integrating standard-of-care guidelines, off-label evidence, and active clinical trials into a unified recommendation. - While the technology exists now, Hwang noted that rigorous testing and regulatory procedures remain necessary before clinical deployment can begin.
- A landmark clinical trial involving over 8,000 children across five countries found no significant difference in kidney complications between balanced crystalloid fluid and 0.9% saline for treating pediatric septic shock. - The study, published in The New England Journal of Medicine, showed major adverse kidney events occurred in 3.4% of children receiving balanced fluid versus 3% receiving saline, with no difference in mortality or hospital length of stay. - Results provide definitive evidence that emergency physicians can confidently use either fluid type as standard care for children with septic shock, ending decades of clinical debate. - While biochemical differences were observed between the two treatments as expected, these did not translate into meaningful clinical outcome differences, confirming both options are safe and effective.
- Aditxt acquired Ignite Proteomics for $36 million through convertible preferred stock to enhance precision oncology capabilities and therapy selection for cancer patients. - Ignite's functional proteomics platform uses Reverse Phase Protein Array technology to analyze protein activity in tumors, providing insights beyond standard genomic testing. - The acquisition targets over 600,000 US patients with metastatic cancer and limited treatment options, addressing a $3 billion serviceable market opportunity in targeted therapies. - Ignite operates a CLIA-certified laboratory with established Medicare reimbursement of approximately $2,200 per test, positioning it for commercial adoption.
- Abbott's CardioMEMS HERO device has received FDA approval as a next-generation pulmonary artery pressure reader for heart failure patients, featuring a 60% lighter design compared to its predecessor. - The HERO reader works with Abbott's implanted CardioMEMS PA sensor to enable daily remote monitoring of pulmonary artery pressures, allowing clinicians to detect worsening heart failure before symptoms appear. - Clinical trials demonstrate the CardioMEMS HF System reduces heart failure hospitalizations by 57% and has been approved for routine NHS use in England after showing 34% reduction in hospital admissions. - The device represents a significant advancement in remote patient monitoring, with integrated Wi-Fi and cellular connectivity enabling patients to take readings virtually anywhere with signal coverage.
- Avobis Bio announced expanded primary analysis results from the STOMP2 trial showing AVB-114 demonstrated similar effectiveness through 9 months with favorable safety and tolerability in both randomized and control cohorts. - The all-treated AVB-114 sample size is nearly double that of the randomized set, providing greater confidence in the therapy's safety and efficacy profile for Crohn's perianal fistulas. - The company has met with the FDA to expedite development plans and is preparing for Phase 3 trials, targeting a condition where two out of three patients do not experience durable healing with current standard of care. - AVB-114 represents the only clinical-stage implantable cell therapy combining living cells with bioabsorbable material to generate tissue and healing signals for this severe Crohn's disease complication.
- Bayer and Vanderbilt University Medical Center announced a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug application. - The partnership will initially focus on cardiovascular and kidney diseases, two therapeutic areas with significant unmet medical need, while spanning across all indications currently pursued by Bayer. - The collaboration will leverage VUMC's comprehensive datasets, including the BioVU collection of DNA and plasma, to enable data-driven insights and accelerate drug discovery and development. - The agreement combines Bayer's expertise in drug discovery and translational sciences with VUMC's deep preclinical and clinical knowledge to advance precision medicine approaches.
